Fmr LLC Dynavax Technologies Corp Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Fmr LLC holds 26,489 shares of DVAX stock, worth $318,397. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,489

Previous 24,827 6.69%

Holding current value

$318,397

Previous $308,000 3.57%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$10.73 - $12.58 $17,833 - $20,907	1,662 Added 6.69%	26,489 $297,000
Q1 2024 May 13, 2024	BUY	$11.7 - $14.98 $11,091 - $14,201	948 Added 3.97%	24,827 $308,000
Q4 2023 Feb 13, 2024	SELL	$13.09 - $14.98 $36,979 - $42,318	-2,825 Reduced 10.58%	23,879 $333,000
Q3 2023 Nov 13, 2023	BUY	$12.64 - $14.99 $47,753 - $56,632	3,778 Added 16.48%	26,704 $394,000
Q2 2023 Aug 11, 2023	BUY	$9.85 - $13.17 $152,448 - $203,832	15,477 Added 207.77%	22,926 $296,000
Q1 2023 May 11, 2023	SELL	$9.44 - $11.88 $3,870 - $4,870	-410 Reduced 5.22%	7,449 $73,000
Q4 2022 Feb 13, 2023	SELL	$10.27 - $13.29 $1,530 - $1,980	-149 Reduced 1.86%	7,859 $83,000
Q3 2022 Nov 10, 2022	BUY	$9.93 - $17.44 $5,501 - $9,661	554 Added 7.43%	8,008 $84,000
Q2 2022 Aug 12, 2022	BUY	$7.45 - $12.83 $17,850 - $30,740	2,396 Added 47.37%	7,454 $94,000
Q1 2022 May 13, 2022	BUY	$9.75 - $14.44 $48,233 - $71,434	4,947 Added 4456.76%	5,058 $55,000
Q4 2021 Feb 14, 2022	SELL	$13.17 - $20.94 $9,219 - $14,658	-700 Reduced 86.31%	111 $2,000
Q3 2021 Nov 15, 2021	BUY	$9.16 - $19.83 $6,164 - $13,345	673 Added 487.68%	811 $15,000
Q2 2021 Aug 13, 2021	BUY	$7.25 - $10.99 $1,000 - $1,516	138 New	138 $1,000

Others Institutions Holding DVAX

# of Institutions

260

Shares Held

132M

Call Options Held

371K

Put Options Held

99.2K

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.52B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account